| Management target | Revenue 17.5% |
|---|
| Revenue growth | 3.93% YoY for Q1 FY27. |
|---|---|
| Margins | EBITDA margin improved to 9.99% from 7.34% YoY. |
| Demand visibility | Strong regulated market pipeline; USFDA/EU GMP clearances secured. |
| Management confidence | High; citing confident opening note for FY27. |
Growth
Revenue reached ₹193.81 Cr; EBITDA rose 41.56% YoY to ₹19.36 Cr; PAT surged 37.63% YoY to ₹11.42 Cr.
Outlook
Management anticipates 15-20% per annum steady growth; four new products under development including Vonoprazon Fumarate and Edoxaban Tosylate.
Risks
Currency risk cited; management is diversifying export markets to mitigate impact. Competitive intensity in generic APIs remains.
Investor Presentation filed with BSE, NSE: ANUHPHR. Summary written with AI assistance from the document.
Anuh Pharma Ltd: key numbers
- Share price
- ₹90.42
- Market cap
- ₹906.2 Cr
- Revenue (annual)
- ₹771.7 Cr
- Net profit (annual)
- ₹41.05 Cr
- P/E (TTM)
- 20.5×Sector 50.4×
- Promoter holding
- 71.80%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anuh Pharma Ltd
All →Anuh Pharma Legal & Regulatory
Anuh Pharma disclosed a Rs. 9,93,206 tax demand under Section 156, Income Tax Act, for AY 2018-19. The company plans to appeal before the CIT.
- Value
- ₹0.10 Cr
Anuh Pharma Q1 FY27 Results: Net Profit ₹11.4 Cr, Up 37.3% YoY
Anuh Pharma Ltd reported revenue from operations of ₹193.8 Cr (+3.9% YoY) and net profit of ₹11.4 Cr (+37.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹11.4 Cr · +37.3% YoY
Anuh Pharma Earnings Call: Key Takeaways
Anuh Pharma reported FY26 revenue growth of 15.66% YoY to ₹776 Cr, driven by strong volumes in regulated markets and successful USFDA/EU GMP inspections.
Anuh Pharma Q4 FY26 Results: Net Profit ₹11.7 Cr, Down 6.4% YoY
Anuh Pharma Ltd reported revenue from operations of ₹202.1 Cr (+2.0% YoY) and net profit of ₹11.7 Cr (-6.4% YoY) for Q4 FY26.
- Key figure
- Net profit ₹11.7 Cr · -6.4% YoY